168 related articles for article (PubMed ID: 30401946)
21. Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation.
Renaudin K; Smati S; Wargny M; Al Ghuzlan A; Aubert S; Leteurtre E; Patey M; Sibony M; Sturm N; Tissier F; Amar L; Bertherat J; Berthozat C; Chabre O; Do Cao C; Haissaguerre M; Pierre P; Briet C; Vezzosi D; Lifante JC; Pattou F; Mirallie E; Baudin E; Cariou B; Libe R; Drui D;
Mod Pathol; 2018 Nov; 31(11):1708-1716. PubMed ID: 29921900
[TBL] [Abstract][Full Text] [Related]
22. Pediatric adrenocortical tumors cohort characteristics and long-term follow-up at a single Argentinian tertiary center.
Mattone MC; Gil S; Costanzo M; Galluzzo Mutti ML; Casanovas A; Zaidman V; Lazzati JM; Ciaccio M; Belgorosky A; Guercio G
J Pediatr Endocrinol Metab; 2022 Jan; 35(1):19-27. PubMed ID: 34674406
[TBL] [Abstract][Full Text] [Related]
23. Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients.
Wieneke JA; Thompson LD; Heffess CS
Am J Surg Pathol; 2003 Jul; 27(7):867-81. PubMed ID: 12826878
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic and prognostic utility of SF1, IGF2 and p57 immunoexpression in pediatric adrenal cortical tumors.
Guntiboina VA; Sengupta M; Islam N; Barman S; Biswas SK; Chatterjee U; Mishra PK; Roy P; Mallick MG; Datta C
J Pediatr Surg; 2019 Sep; 54(9):1906-1912. PubMed ID: 30686519
[TBL] [Abstract][Full Text] [Related]
25. Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma.
Poli G; Ruggiero C; Cantini G; Canu L; Baroni G; Armignacco R; Jouinot A; Santi R; Ercolino T; Ragazzon B; Assie G; Mannelli M; Nesi G; Lalli E; Luconi M
J Clin Endocrinol Metab; 2019 May; 104(5):1712-1724. PubMed ID: 30476173
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic and prognostic utility of SF-1 in adrenal cortical tumours.
Maity P; Mondal A; Das R; Sengupta M; Gargari P; Kar A; Sarkar D; Mukhopadhyay S; Chowdhury S; Chatterjee U
Indian J Pathol Microbiol; 2022; 65(4):814-820. PubMed ID: 36308186
[TBL] [Abstract][Full Text] [Related]
27. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization.
Stojadinovic A; Ghossein RA; Hoos A; Nissan A; Marshall D; Dudas M; Cordon-Cardo C; Jaques DP; Brennan MF
J Clin Oncol; 2002 Feb; 20(4):941-50. PubMed ID: 11844815
[TBL] [Abstract][Full Text] [Related]
28. Validation of the prognostic role of the "Helsinki Score" in 225 cases of adrenocortical carcinoma.
Duregon E; Cappellesso R; Maffeis V; Zaggia B; Ventura L; Berruti A; Terzolo M; Fassina A; Volante M; Papotti M
Hum Pathol; 2017 Apr; 62():1-7. PubMed ID: 27916625
[TBL] [Abstract][Full Text] [Related]
29. Validation of a Cytotechnologist Manual Counting Service for the Ki67 Index in Neuroendocrine Tumors of the Pancreas and Gastrointestinal Tract.
Cottenden J; Filter ER; Cottreau J; Moore D; Bullock M; Huang WY; Arnason T
Arch Pathol Lab Med; 2018 Mar; 142(3):402-407. PubMed ID: 29293020
[TBL] [Abstract][Full Text] [Related]
30. Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma.
Duregon E; Molinaro L; Volante M; Ventura L; Righi L; Bolla S; Terzolo M; Sapino A; Papotti MG
Mod Pathol; 2014 Sep; 27(9):1246-54. PubMed ID: 24434900
[TBL] [Abstract][Full Text] [Related]
31. Paradoxical results obtained with Ki67-labeling and PHH3-mitosis index in glial tumors: a literature analysis.
Elmaci İ; Altinoz MA; Bolukbasi FH; Yapicier O; Sav A
Clin Neuropathol; 2017; 36(6):272-282. PubMed ID: 28853695
[TBL] [Abstract][Full Text] [Related]
32. Adrenocortical tumors in Brazilian children: immunohistochemical markers and prognostic factors.
Sbragia L; Oliveira-Filho AG; Vassallo J; Pinto GA; Guerra-Junior G; Bustorff-Silva J
Arch Pathol Lab Med; 2005 Sep; 129(9):1127-31. PubMed ID: 16119984
[TBL] [Abstract][Full Text] [Related]
33. Adrenal cortical tumors in children: factors associated with poor outcome.
Klein JD; Turner CG; Gray FL; Yu DC; Kozakewich HP; Perez-Atayde AR; Voss SD; Zurakowski D; Shamberger RC; Weldon CB
J Pediatr Surg; 2011 Jun; 46(6):1201-7. PubMed ID: 21683223
[TBL] [Abstract][Full Text] [Related]
34. Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children's Oncology Group Study.
Pinto EM; Rodriguez-Galindo C; Pounds SB; Wang L; Clay MR; Neale G; Garfinkle EAR; Lam CG; Levy CF; Pappo AS; Zambetti GP; Ribeiro RC
J Clin Oncol; 2017 Dec; 35(35):3956-3963. PubMed ID: 29058986
[TBL] [Abstract][Full Text] [Related]
35. [Tissue heterogeneity contributes to suboptimal precision of WHO 2010 scoring criteria for Ki67 labeling index in a subset of neuroendocrine neoplasms of the pancreas].
Liszka Ł
Pol J Pathol; 2016; 67(4):318-331. PubMed ID: 28547959
[TBL] [Abstract][Full Text] [Related]
36. Transformation in recurrent ovarian granulosa cell tumors: Ki67 (MIB-1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior.
Costa MJ; Walls J; Ames P; Roth LM
Hum Pathol; 1996 Mar; 27(3):274-81. PubMed ID: 8600043
[TBL] [Abstract][Full Text] [Related]
37. Twenty-seven cases of pineal parenchymal tumours of intermediate differentiation: mitotic count, Ki-67 labelling index and extent of resection predict prognosis.
Yu T; Sun X; Wang J; Ren X; Lin N; Lin S
J Neurol Neurosurg Psychiatry; 2016 Apr; 87(4):386-95. PubMed ID: 25911570
[TBL] [Abstract][Full Text] [Related]
38. Adrenocortical oncocytic tumors: report of 10 cases and review of the literature.
Bisceglia M; Ludovico O; Di Mattia A; Ben-Dor D; Sandbank J; Pasquinelli G; Lau SK; Weiss LM
Int J Surg Pathol; 2004 Jul; 12(3):231-43. PubMed ID: 15306935
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series.
Tőke J; Uhlyarik A; Lohinszky J; Stark J; Huszty G; Micsik T; Borka K; Reismann P; Horányi J; Igaz P; Tóth M
Front Endocrinol (Lausanne); 2022; 13():952418. PubMed ID: 36246926
[TBL] [Abstract][Full Text] [Related]
40. Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma.
Sasano H; Satoh F; Nakamura Y
Endocr Pathol; 2014 Dec; 25(4):366-70. PubMed ID: 25252621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
